Replies to post #119075 on Biotech Values

[genisi]

Higher Lucentis dose (2mg) is dead but monthly vs. an As-Needed Basis (PRN) perhaps not:

Here not so good news is that the HARBOR study is clearly showing us that high-dose approach with Lucentis will not be an option. We were not able to show the superiority of this high-dose approach and we are still analyzing the data as far as the PRN versus monthly comparison.

See mid page 4: http://www.morningstar.com/earnings/31452276-roche-holding-ag-adr-rhhby-q3-2011.aspx?pindex=4